ArticleInfluenza and other respiratory viruses2026
Influenza Antiviral Prescriptions in the US Inpatient and Outpatient Settings During the 2015-2022 Influenza Seasons.
Article in Influenza and other respiratory viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundsThe antiviral drug prescription landscape has changed as new antivirals for influenza treatment have been approved. Understanding this landscape is important to assess potential under- and mis-utilization and to address gaps in care. This study characterizes patterns in influenza antiviral use in US healthcare settings using a large claims database.
methodsWe included prescriptions of four antivirals: oseltamivir, baloxavir, peramivir, and zanamivir in US healthcare settings between September 2016 and August 2023, using Komodo Health Database. We estimated the percentage of antiviral prescriptions associated with respiratory disease diagnoses, including influenza, COVID-19, and other respiratory conditions, and the percentage prescribed to patients at high risk of influenza complications. We used multinomial logistic regression to assess the association between patient and prescriber characteristics and the choice of antiviral.
resultsBetween 865,885 and 3,092,822 influenza antiviral prescriptions were filled annually during the 2016-2017 through 2022-2023 influenza seasons among US insured individuals. Oseltamivir was the most prevalent antiviral type. Baloxavir use remained low, accounting for 1.8%-9.2% of total prescriptions since its 2018 approval. Between 55.6% and 75.4% of prescriptions had an associated influenza diagnosis, with the lowest proportion observed during the 2020-2021 season. Between 2.59% and 5.35% of antivirals were prescribed to high-risk patients. Influenza diagnosis and patient age were associated with prescribing baloxavir rather than oseltamivir.
conclusionsAmong US insured individuals, oseltamivir remained the most prescribed antiviral during the 2016-2017 through 2022-2023 seasons, a pattern consistent with its broader FDA-approved indication across age groups and care settings relative to baloxavir, peramivir, and zanamivir.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.